The plasma genotyping of EGFR-mutant NSCLC is also highly valuable during treatment as an indicator of tumor response or disease progression by evaluating variant allelic fractions of genomic alterations and detecting the emergence of resistance mechanisms earlier. This evidence concerns the gene EGFR and neoplasm.